Suresh Rav

Suresh Rav

Associate | Litigation
617.646.8585 Suresh.Rav@WolfGreenfield.com

Education

  • University of Pittsburgh, BS, Biological Sciences and History, magna cum laude
  • The George Washington University Law School, JD, with honors

Practice Groups

Location

  • Boston

Overview

Suresh Rav focuses his practice on patent litigation. 

Prior to joining the firm full time, Suresh graduated from The George Washington University Law School and spent the summer of 2020 as a summer associate in Wolf Greenfield’s Litigation Practice. As a summer associate, Suresh assisted with various cases and drafted documents relating to pro bono matters for the firm. 

While in law school, Suresh was a member of the Federal Communications Law Journal, the Moot Court Board, and the Alternative Dispute Resolution Board. He also served as a judicial intern for the US District Court for the Western District of Pennsylvania, where he gained experience researching substantive and procedural issues on civil and criminal motions before the court and assisted the Judge’s clerks in preparation for a multi-week jury trial. Suresh also externed with the Intellectual Property Section of the US Department of Justice, where he researched case law and drafted a pleading covering several trademark and copyright issues.

Prior to law school, Suresh was a Quality Control Scientist at GMP Nutraceuticals. While there, he oversaw regulatory compliance for the manufacturing facility in accordance with FDA regulatory guidance. While at GMP Nutraceuticals, Suresh also formulated proprietary blends for dietary supplements based on client specifications.


Publications

See All Publications
(SizeLimitingPyList: [{year_group=2022, publish_date=2022-03-09 05:00:00, name=The Federal Circuit Rejects Admitted Prior Art as the “Basis” for IPR Proceedings, absolute_url=https://wolfgreenfield.com/publications/articles/the-federal-circuit-rejects-admitted-prior-art-as-the-basis-for-ipr-proceedings}, {year_group=2020, publish_date=2020-09-11 04:00:00, name=One and Done: Federal Circuit Affirms No New Notice Requirement Under BPCIA for Supplement to aBLA That Does Not Alter Biosimilar Structure, absolute_url=https://wolfgreenfield.com/publications/articles/federal-circuit-affirms-no-new-notice-requirement-under-bpcia-for-supplement-to-abla-that-does-not-alter-biosimilar-structure}, {year_group=2020, publish_date=2020-08-05 04:00:00, name=One Size Does Not Fit All: Courts Exercise Discretion in Addressing the Need for Remote Depositions in the Wake of COVID-19, absolute_url=https://wolfgreenfield.com/publications/articles/2020/one-size-does-not-fit-all-courts-exercise-discretion-in-addressing-the-need-for-remote-depositions}, {year_group=2020, publish_date=2020-06-19 04:00:00, name=Remote Depositions During COVID-19 and Beyond, absolute_url=https://wolfgreenfield.com/publications/articles/2020/remote-depositions-during-covid19-and-beyond}])
2022 2020